AI reshapes drug R&D, but limits remain

Panelists said the industry is still in the early stages of integrating AI into research and development.

Panelists for the AI in BioPharma R&D - Hype vs. Reality panel

Credit: USAIC

Share this Article:

Staff Reporter

Author

View Profile

View Profile